工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
从保存的人肿瘤组织标本中分离 TIL（肿瘤浸润淋巴细胞）用于下游表征
英文原题：Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization.
查看英文原题
Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
流式细胞术对TIL（肿瘤浸润淋巴细胞）进行免疫表型分析可预测免疫治疗疗效，但从实体瘤标本建立流式检测方法仍面临若干障碍。本文提供一种详细酶法流程，用于从人肿瘤组织中分离TIL。该流程经过优化，可从活检组织获得足量存活TIL，以供流式免疫表型分析；组织样本还可保存最长72小时再进行后续表征。该流程的完整细节及操作说明请参阅Kumagai等（2020、2022年）。
展开英文摘要原文
Immunophenotyping of tumor-infiltrating lymphocytes (TILs) by flow cytometry can predict clinical efficacy of immunotherapy.
However, several obstacles need to be overcome for developing a flow cytometry assay starting from solid tumor specimens.
Here, we show a detailed enzyme-based protocol to isolate TILs from human tumor tissues. The protocol was optimized to obtain enough viable TILs from a biopsy tissue specimen for flow cytometry-based TIL immunophenotyping.
Additionally, tissue samples could be preserved for up to 72 h for subsequent characterization. For complete details on the use and execution of this protocol, please refer to Kumagai et al. (2020, 2022).
论文信息
- 作者
- Kobayashi T、Kumagai S、Doi R、Afonina E、Koyama S、Nishikawa H
- 第一作者单位
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba 104-0045/277-8577, Japan; Becton, Dickinson and Company, Biosciences, Tokyo 107-0052, Japan. Electronic address: tamiyo.kobayashi@bd.com.Japan
- 通讯作者单位
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba 104-0045/277-8577, Japan; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. Electronic address: hnishika@ncc.go.jp.Japan
- 文献类型
- 非美国政府资助研究
- 期刊
- STAR protocols2022 Sep 16
- 原文标识
- PubMed 35852944 · DOI 10.1016/j.xpro.2022.101557
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →